Table 3.
Soluble and insoluble amyloid-beta levels measured by ELISA
| |
Soluble (pg/μg protein) |
Insoluble (pg/μg protein) |
|||||
|---|---|---|---|---|---|---|---|
| AAV injection | Survival (months) | Aβ1-38 | Aβ1-40 | Aβ1-42 | Aβ1-38 | Aβ1-40 | Aβ1-42 |
| GFP-AAV |
4 |
1.67 ± 0.77 |
2.97 ± 0.28 |
12.90 ± 2.24 |
9.04 ± 1.99 |
98.70 ± 36.77 |
903.27 ± 56.1 |
| GFP-AAV |
6 |
3.16 ± 0.75 |
5.10 ± 0.44 |
25.37 ± 3.81 |
23.82 ± 2.83 |
335.53 ± 64.95 |
1634.87 ± 397.9 |
| IFNγ-AAV |
4 |
3.68 ± 0.23 |
5.41 ± 0.91 |
27.17 ± 4.94 |
20.56 ± 8.48 |
295.78 ± 87.63 |
2855.26 ± 1267.9 |
| IFNγ-AAV | 6 | 4.95 ± 0.51 | 6.57 ± 0.89 | 38.90 ± 7.35 | 27.10 ± 4.10 | 269.72 ± 55.2 | 2047.32 ± 436.0 |
Bold indicates P < 0.05 compared to GFP-AAV at the same time point. Aβ, amyloid-beta; AAV, adeno-associated virus; ELISA, enzyme-linked immunosorbent assay; IFN, interferon.